Posted by Michael Wonder on 07 Apr 2018
Roche cops another rejection from NICE
6 April 2018 - Second rebuttal from NICE in as many days.
NICE has published an appraisal consultation document on the use of alectinib hydrochloride (Alecensa) for patients with untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
NICE has recommended against its use in the National Health Service. Using the most plausible assumptions, the cost-effectiveness estimates for alectinib hydrochloride compared with crizotinib were above the range that the committee considered to be cost-effective.
